major depression
Coverage of major depression in the Nexus archive.
- Definium’s shares surge 55% after LSD-based depression pill delivers strong results
Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced major depression symptoms in a late-stage trial, leading to a 55% surge in its shares to a four-year high. Patients on the drug recorded lower depression scale scores than those on placebo after six weeks.
- STAT+: Definium LSD therapy helped patients with major depression in late-stage trial
Definium Therapeutics' LSD therapy (DT120) showed significant improvement in patients with major depression during a Phase 3 trial. Patients experienced a 13.3-point drop on the MADRS depression test at six weeks compared to 5.2 points in the placebo group, with effects maintained at 12 weeks.
- FDA grants quick review for 3 psychedelic drug trials
The FDA has expedited the review of three experimental psychedelic drugs intended to treat major depression and post-traumatic stress disorder. NBC News' Erika Edwards highlights the FDA's evaluation process for safety and efficacy of these drugs.